India and Brazil signed an agreement to cooperate on pharmaceutical regulations, aiming to improve safety, quality, and access to medical products.

Gilead acquires Arcellx for $7.8B to gain control of anito-cel, a potential multiple myeloma therapy, with deal closing in Q2 2026.

FDA proposes fast-tracking gene therapies for rare diseases with strong scientific basis.

A UK baby, Hugo Powell, is the first born from a womb transplant using a deceased donor, offering new hope for women with uterine infertility.

Eli Lilly's orforglipron outperformed semaglutide in lowering blood sugar and weight in type 2 diabetes patients, with FDA decision expected in Q2 2026.

Eris and Natco to launch generic semaglutide in India in March 2026 post-patent expiry.

Novo Nordisk cuts U.S. prices for Ozempic and Wegovy by up to 50% starting Jan. 1, 2027, to boost affordability.

A small U.S. trial found placenta-derived stem cells given during fetal surgery for spina bifida were safe and improved motor function and brain abnormalities in six infants.

India’s pharma exports hit $30.5B in 2024–25, with goals to reach $130B by 2030.

Novo Nordisk's stock dropped to a five-year low after its weight-loss drug underperformed Eli Lilly’s, despite strong financials.